We are live on ! Find out more
BOLD

Audentes Therapeutics, Inc
BOLD

Delisted

BOLD was delisted on the 14th of January, 2020.

57 hedge funds and large institutions have $283M invested in Audentes Therapeutics, Inc in 2016 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

16% more funds holding

Funds holding: 4957 (+8)

4% more capital invested

Capital invested by funds: $272M → $283M (+$10.8M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

7% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 14

Holders
57
Holders Change
+8
Holders Change %
+16.33%
% of All Funds
1.42%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
13
Increased
13
Reduced
14
Closed
5
Calls
Puts
Net Calls
Net Calls Change

BOLD Hedge Fund Activity: Q4 2016 in Review

57 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q4 2016, worth a combined $283M — up 4% from $272M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new BOLD positions and 5 closed out — a net gain of 8 holders — while 13 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $5.61M. The largest seller was RA Capital Management, cutting an estimated $3.02M.

  • 57 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q4 2016, up from 49 in Q3 2016.
  • Funds reported $283M of Audentes Therapeutics, Inc stock for Q4 2016, up 4% quarter-over-quarter.
  • 13 funds opened new Audentes Therapeutics, Inc positions in Q4 2016 and 5 closed out, a net change of +8 holders.
  • The largest Audentes Therapeutics, Inc buyer in Q4 2016 was BlackRock Fund Advisors, an estimated $5.61M added.
  • The largest Audentes Therapeutics, Inc seller in Q4 2016 was RA Capital Management, an estimated $3.02M sold.

Based on aggregated 13F filings for Q4 2016.